FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1808883145> ?p ?o ?g. }

• W1808883145 endingPage "473" @default.
• W1808883145 startingPage "465" @default.
• W1808883145 abstract "WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Children are entitled to safe, efficacious, child and parent friendly (i.e. age‐appropriate) medicines. However, off‐label and unlicensed paediatric prescription rates in hospital range from 36% (surgical and medical wards) to 93% (neonatal wards), which indicates a general lack of age‐appropriate medicines for children. In 2007, the European Union issued the Paediatric Regulation aiming at better medicines for children by, for example, increasing the number of authorized paediatric medicines. WHAT THIS STUDY ADDS • This study reviews the availability and age‐appropriateness of medicines for children in the Netherlands, herewith providing a baseline for an estimation of the effect of the European Paediatric Regulation in the near future. This study also provides a tool for the evaluation of the child authorization status of medicines on the basis of the information in the Summary of Product Characteristics (SPC) and for the assessment of key aspects of the age‐appropriateness of paediatric formulations. AIM To study the number of medicines and active chemical entities that are authorized and commercially available for children in the Netherlands and to evaluate the age‐appropriateness of the available paediatric medicines. METHODS The availability of paediatric medicines and active chemical entities was studied with the help of a Dutch medicines database and the Summary of Product Characteristics. Medicines were categorized with respect to their route of administration, type of oral dosage form and therapeutic category. The age‐appropriateness was assessed on three aspects: dose capability, suitability of the dosage form and inclusion of potentially harmful excipients. RESULTS Three thousand five hundred and forty‐two paediatric medicines containing 703 different active chemical entities were identified. This equalled half of all the medicines and chemical entities available for human use. The percentage of paediatric medicines increased with age and varied for the route of administration from 22% (dermal) to 81% (inhalation) and for the therapeutic category from 11% (uro‐genital, sex hormones) to 89% (anti‐parasites). The appropriateness of the paediatric medicines with respect to their authorization status, dose capability and dosage form increased with age from 27–88%. Fifty‐two percent of all oral paediatric liquid formulations contained a potentially harmful excipient. CONCLUSION This study confirms the limited availability of paediatric medicines for a broad range of therapeutic areas and shows that paediatric medicines may not be age‐appropriate, even if authorized. While confirming the need for a legislative incentive, the results also provide baseline information for an estimation of the effect of the European Paediatric Regulation in the near future." @default.
• W1808883145 created "2016-06-24" @default.
• W1808883145 creator A5024452963 @default.
• W1808883145 creator A5024588131 @default.
• W1808883145 creator A5064803155 @default.
• W1808883145 creator A5079074915 @default.
• W1808883145 creator A5087254353 @default.
• W1808883145 date "2011-08-08" @default.
• W1808883145 modified "2023-10-17" @default.
• W1808883145 title "The availability and age-appropriateness of medicines authorized for children in the Netherlands" @default.
• W1808883145 cites W1588753918 @default.
• W1808883145 cites W1977234490 @default.
• W1808883145 cites W2014148385 @default.
• W1808883145 cites W2034994020 @default.
• W1808883145 cites W2037556399 @default.
• W1808883145 cites W2047719593 @default.
• W1808883145 cites W2061170526 @default.
• W1808883145 cites W2073883467 @default.
• W1808883145 cites W2074115747 @default.
• W1808883145 cites W2078566398 @default.
• W1808883145 cites W2101361577 @default.
• W1808883145 cites W2144462910 @default.
• W1808883145 cites W2147291501 @default.
• W1808883145 cites W2147899247 @default.
• W1808883145 cites W2151161482 @default.
• W1808883145 cites W2156631317 @default.
• W1808883145 cites W2075733365 @default.
• W1808883145 doi "https://doi.org/10.1111/j.1365-2125.2011.03982.x" @default.
• W1808883145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3175516" @default.
• W1808883145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21477143" @default.
• W1808883145 hasPublicationYear "2011" @default.
• W1808883145 type Work @default.
• W1808883145 sameAs 1808883145 @default.
• W1808883145 citedByCount "44" @default.
• W1808883145 countsByYear W18088831452012 @default.
• W1808883145 countsByYear W18088831452013 @default.
• W1808883145 countsByYear W18088831452014 @default.
• W1808883145 countsByYear W18088831452015 @default.
• W1808883145 countsByYear W18088831452016 @default.
• W1808883145 countsByYear W18088831452017 @default.
• W1808883145 countsByYear W18088831452018 @default.
• W1808883145 countsByYear W18088831452019 @default.
• W1808883145 countsByYear W18088831452020 @default.
• W1808883145 countsByYear W18088831452021 @default.
• W1808883145 countsByYear W18088831452022 @default.
• W1808883145 countsByYear W18088831452023 @default.
• W1808883145 crossrefType "journal-article" @default.
• W1808883145 hasAuthorship W1808883145A5024452963 @default.
• W1808883145 hasAuthorship W1808883145A5024588131 @default.
• W1808883145 hasAuthorship W1808883145A5064803155 @default.
• W1808883145 hasAuthorship W1808883145A5079074915 @default.
• W1808883145 hasAuthorship W1808883145A5087254353 @default.
• W1808883145 hasBestOaLocation W18088831452 @default.
• W1808883145 hasConcept C105639569 @default.
• W1808883145 hasConcept C108759981 @default.
• W1808883145 hasConcept C144133560 @default.
• W1808883145 hasConcept C187212893 @default.
• W1808883145 hasConcept C188313352 @default.
• W1808883145 hasConcept C2426938 @default.
• W1808883145 hasConcept C2777436895 @default.
• W1808883145 hasConcept C2777589142 @default.
• W1808883145 hasConcept C2910001868 @default.
• W1808883145 hasConcept C38652104 @default.
• W1808883145 hasConcept C41008148 @default.
• W1808883145 hasConcept C512399662 @default.
• W1808883145 hasConcept C60644358 @default.
• W1808883145 hasConcept C71924100 @default.
• W1808883145 hasConcept C86803240 @default.
• W1808883145 hasConcept C98274493 @default.
• W1808883145 hasConceptScore W1808883145C105639569 @default.
• W1808883145 hasConceptScore W1808883145C108759981 @default.
• W1808883145 hasConceptScore W1808883145C144133560 @default.
• W1808883145 hasConceptScore W1808883145C187212893 @default.
• W1808883145 hasConceptScore W1808883145C188313352 @default.
• W1808883145 hasConceptScore W1808883145C2426938 @default.
• W1808883145 hasConceptScore W1808883145C2777436895 @default.
• W1808883145 hasConceptScore W1808883145C2777589142 @default.
• W1808883145 hasConceptScore W1808883145C2910001868 @default.
• W1808883145 hasConceptScore W1808883145C38652104 @default.
• W1808883145 hasConceptScore W1808883145C41008148 @default.
• W1808883145 hasConceptScore W1808883145C512399662 @default.
• W1808883145 hasConceptScore W1808883145C60644358 @default.
• W1808883145 hasConceptScore W1808883145C71924100 @default.
• W1808883145 hasConceptScore W1808883145C86803240 @default.
• W1808883145 hasConceptScore W1808883145C98274493 @default.
• W1808883145 hasIssue "3" @default.
• W1808883145 hasLocation W18088831451 @default.
• W1808883145 hasLocation W18088831452 @default.
• W1808883145 hasLocation W18088831453 @default.
• W1808883145 hasLocation W18088831454 @default.
• W1808883145 hasOpenAccess W1808883145 @default.
• W1808883145 hasPrimaryLocation W18088831451 @default.
• W1808883145 hasRelatedWork W1513425378 @default.
• W1808883145 hasRelatedWork W1991412514 @default.
• W1808883145 hasRelatedWork W2060068399 @default.
• W1808883145 hasRelatedWork W2069460520 @default.
• W1808883145 hasRelatedWork W2073417023 @default.
• W1808883145 hasRelatedWork W2419206643 @default.

• next